Legend Biotech Corporation, a leader in cell therapy, announced positive results from its Phase 2 CARTITUDE-2 Cohort D study, demonstrating the efficacy of CARVYKTI in treating multiple myeloma patients. CARVYKTI, approved for relapsed/refractory multiple myeloma, showed promising results in patients with less than a complete response after autologous stem cell transplant (ASCT).
The study enrolled 17 patients who received a single infusion of CARVYKTI with or without lenalidomide maintenance. At a median follow-up of 22 months, 94% of patients achieved an overall response, with 16 patients achieving a complete response or better. The median duration of response was not reached, and the median time to first response was one month.
CARVYKTI also demonstrated improved progression-free survival and overall survival rates, exceeding 90% at 18 months. Safety signals were consistent with the known profile of CARVYKTI, with no cases of movement and neurocognitive treatment-emergent adverse events.
Legend Biotech is optimistic about CARVYKTI’s potential in earlier treatment settings for multiple myeloma. Phase 3 studies are underway to explore its benefits as a frontline treatment option.
Additionally, a subgroup analysis from the CARTITUDE-4 Phase 3 study showed that CARVYKTI significantly improved progression-free survival compared to standard therapies in patients with high-risk multiple myeloma. These results highlight the potential role of CARVYKTI in improving outcomes for multiple myeloma patients in various stages of their treatment journey.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
